1. How would you evaluate the RoboTech’s first 3 years in the US Medical device market? What do you think it has done most effectively? Where has it fallen short?
2. What should Chen do now? How would the company move forward into 2017 and beyond? Which, if any, of the proposed capital investments should it make?